Literature DB >> 15790771

The kinetic status of hematopoietic stem cell subpopulations underlies a differential expression of genes involved in self-renewal, commitment, and engraftment.

Rossella Manfredini1, Roberta Zini, Simona Salati, Michela Siena, Elena Tenedini, Enrico Tagliafico, Monica Montanari, Tommaso Zanocco-Marani, Claudia Gemelli, Tatiana Vignudelli, Alexis Grande, Miriam Fogli, Lara Rossi, Maria Elena Fagioli, Lucia Catani, Roberto M Lemoli, Sergio Ferrari.   

Abstract

The gene expression profile of CD34(-) hematopoietic stem cells (HSCs) and the correlations with their biological properties are still poorly understood. To address this issue, we used the DNA microarray technology to compare the expression profiles of different peripheral blood hemopoietic stem/progenitor cell subsets, lineage-negative (Lin(-)) CD34(-), Lin(-)CD34(+), and Lin(+)CD34(+) cells. The analysis of gene categories differentially expressed shows that the expression of CD34 is associated with cell cycle entry and metabolic activation, such as DNA, RNA, and protein synthesis. Moreover, the significant upregulation in CD34(-) cells of pathways inhibiting HSC proliferation induces a strong differential expression of cyclins, cyclin-dependent kinases (CDKs), CDK inhibitors, and growth-arrest genes. According to the expression of their receptors and transducers, interleukin (IL)-10 and IL-17 showed an inhibitory effect on the clonogenic activity of CD34(-) cells. Conversely, CD34(+) cells were sensitive to the mitogenic stimulus of thrombopoietin. Furthermore, CD34(-) cells express preferentially genes related to neural, epithelial, and muscle differentiation. The analysis of transcription factor expression shows that the CD34 induction results in the upregulation of genes related to self-renewal and lineage commitment. The preferential expression in CD34(+) cells of genes supporting the HSC mobilization and homing to the bone marrow, such as chemokine receptors and integrins, gives the molecular basis for the higher engraftment capacity of CD34(+) cells. Thus, the different kinetic status of CD34(-) and CD34(+) cells, detailed by molecular and functional analysis, significantly influences their biological behavior.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15790771     DOI: 10.1634/stemcells.2004-0265

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  12 in total

1.  Not just a marker: CD34 on human hematopoietic stem/progenitor cells dominates vascular selectin binding along with CD44.

Authors:  Dina B AbuSamra; Fajr A Aleisa; Asma S Al-Amoodi; Heba M Jalal Ahmed; Chee Jia Chin; Ayman F Abuelela; Ptissam Bergam; Rachid Sougrat; Jasmeen S Merzaban
Journal:  Blood Adv       Date:  2017-12-26

2.  Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.

Authors:  Rocco Piazza; Simona Valletta; Nils Winkelmann; Sara Redaelli; Roberta Spinelli; Alessandra Pirola; Laura Antolini; Luca Mologni; Carla Donadoni; Elli Papaemmanuil; Susanne Schnittger; Dong-Wook Kim; Jacqueline Boultwood; Fabio Rossi; Giuseppe Gaipa; Greta P De Martini; Paola Francia di Celle; Hyun Gyung Jang; Valeria Fantin; Graham R Bignell; Vera Magistroni; Torsten Haferlach; Enrico Maria Pogliani; Peter J Campbell; Andrew J Chase; William J Tapper; Nicholas C P Cross; Carlo Gambacorti-Passerini
Journal:  Nat Genet       Date:  2012-12-09       Impact factor: 38.330

3.  Extramedullary hematopoiesis is dysregulated in histamine-free histidine decarboxylase knockout (HDC-/-) mice.

Authors:  Zsuzsanna Horváth; Eva Pállinger; Gyozo Horváth; Ivett Jelinek; Gizella Veszely; József Furész; András Falus; Edit I Buzás
Journal:  Inflamm Res       Date:  2009-11-19       Impact factor: 4.575

4.  HOXD13 binds DNA replication origins to promote origin licensing and is inhibited by geminin.

Authors:  Valentina Salsi; Silvia Ferrari; Roberta Ferraresi; Andrea Cossarizza; Alexis Grande; Vincenzo Zappavigna
Journal:  Mol Cell Biol       Date:  2009-08-24       Impact factor: 4.272

5.  Integrated analysis of microRNA and mRNA expression profiles in physiological myelopoiesis: role of hsa-mir-299-5p in CD34+ progenitor cells commitment.

Authors:  E Tenedini; E Roncaglia; F Ferrari; C Orlandi; E Bianchi; S Bicciato; E Tagliafico; S Ferrari
Journal:  Cell Death Dis       Date:  2010       Impact factor: 8.469

6.  Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value.

Authors:  A M Vannucchi; G Rotunno; N Bartalucci; G Raugei; V Carrai; M Balliu; C Mannarelli; A Pacilli; L Calabresi; R Fjerza; L Pieri; A Bosi; R Manfredini; P Guglielmelli
Journal:  Leukemia       Date:  2014-03-12       Impact factor: 11.528

7.  Genome-wide analysis of immune activation in human T and B cells reveals distinct classes of alternatively spliced genes.

Authors:  Yevgeniy A Grigoryev; Sunil M Kurian; Aleksey A Nakorchevskiy; John P Burke; Daniel Campbell; Steve R Head; Jun Deng; Aaron B Kantor; John R Yates; Daniel R Salomon
Journal:  PLoS One       Date:  2009-11-19       Impact factor: 3.240

8.  Co-culture of hematopoietic stem/progenitor cells with human osteblasts favours mono/macrophage differentiation at the expense of the erythroid lineage.

Authors:  Simona Salati; Gina Lisignoli; Cristina Manferdini; Valentina Pennucci; Roberta Zini; Elisa Bianchi; Ruggiero Norfo; Andrea Facchini; Sergio Ferrari; Rossella Manfredini
Journal:  PLoS One       Date:  2013-01-22       Impact factor: 3.240

9.  Genomic expression during human myelopoiesis.

Authors:  Francesco Ferrari; Stefania Bortoluzzi; Alessandro Coppe; Dario Basso; Silvio Bicciato; Roberta Zini; Claudia Gemelli; Gian Antonio Danieli; Sergio Ferrari
Journal:  BMC Genomics       Date:  2007-08-03       Impact factor: 3.969

10.  Remodeling of nuclear landscapes during human myelopoietic cell differentiation maintains co-aligned active and inactive nuclear compartments.

Authors:  Barbara Hübner; Mariana Lomiento; Fabiana Mammoli; Doris Illner; Yolanda Markaki; Sergio Ferrari; Marion Cremer; Thomas Cremer
Journal:  Epigenetics Chromatin       Date:  2015-11-17       Impact factor: 4.954

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.